Kraj: Stany Zjednoczone
Język: angielski
Źródło: NLM (National Library of Medicine)
CEFOTAXIME SODIUM (UNII: 258J72S7TZ) (CEFOTAXIME - UNII:N2GI8B1GK7)
Wockhardt USA LLC.
CEFOTAXIME SODIUM
CEFOTAXIME 500 mg
INTRAMUSCULAR
PRESCRIPTION DRUG
Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species,
Sterile Cefotaxime for injection, USP is a dry off-white to pale yellow crystalline powder supplied in vials containing cefotaxime sodium as follows: 500 mg cefotaxime (free acid equivalent) in vials in packages of: Package of 1 NDC 64679-947-01 Package of 10 NDC 64679-947-02 1 g cefotaxime (free acid equivalent) in vials in packages of: Package of 1 NDC 64679-986-01 Package of 10 NDC 64679-986-02 Package of 25 NDC 64679-986-03 Package of 50 NDC 64679-986-04 2 g cefotaxime (free acid equivalent) in vials in packages of: Package of 1 NDC 64679-948-01 Package of 10 NDC 64679-948-02 NOTE : Cefotaxime for injection, USP in the dry state, store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. The dry material as well as solutions tend to darken depending on storage conditions and should be protected from elevated temperatures and excessive light.
Abbreviated New Drug Application
CEFOTAXIME- CEFOTAXIME INJECTION, POWDER, FOR SOLUTION WOCKHARDT USA LLC. ---------- PRESCRIBING INFORMATION CEFOTAXIME FOR INJECTION, USP TO REDUCE THE DEVELOPMENT OF DRUG-RESISTANT BACTERIA AND MAINTAIN THE EFFECTIVENESS OF CEFOTAXIME FOR INJECTION AND OTHER ANTIBACTERIAL DRUGS, CEFOTAXIME FOR INJECTION SHOULD BE USED ONLY TO TREAT OR PREVENT INFECTIONS THAT ARE PROVEN OR STRONGLY SUSPECTED TO BE CAUSED BY BACTERIA. DESCRIPTION Cefotaxime for injection, USP is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It is the sodium salt of 7-[2-(2-amino-4-thiazolyl) glyoxylamido]-3- (hydroxymethyl)-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate 72 (Z)-(o-methyloxime), acetate (ester). Cefotaxime for injection, USP contains approximately 50.5 mg (2.2 mEq) of sodium per gram of cefotaxime activity. Solutions of cefotaxime for injection, USP range from very pale yellow to light amber depending on the concentration and the diluent used. The pH of the injectable solutions usually ranges from 5.0 to 7.5. The CAS Registry Number is 64485-93-4. The molecular formula is C H N NaO S and the molecular weight is 477.45. Cefotaxime for injection, USP is supplied as a dry powder in conventional vials. Each vial contains cefotaxime sodium equivalent to 500 mg, 1 g or 2 g of cefotaxime. CLINICAL PHARMACOLOGY Following IM administration of a single 500 mg or 1 g dose of cefotaxime for injection to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour. There was a dose- dependent increase in serum levels after the IV administration of 500 mg, 1 g, and 2 g of cefotaxime for injection (38.9, 101.7, and 214.4 mcg/mL respectively) without alteration in the elimination half-life. There is no evidence of accumulation following repetitive IV infusion of 1 g doses every 6 hours for 14 days as there are no alterations of serum or renal clearance. About 60% of the ad Przeczytaj cały dokument